Mesoblast enrolls patients in end-stage heart failure therapy trial

Company News

by Jessica Amir

Mesoblast (ASX:MSB) has enrolled 159-patients into its clinical trial for cell therapy on end-stage heart failure patients.

The regenerative medicine company’s trial involves its novel allogeneic MPC therapy (mesenchymal precursor cell (MPC)) on heart failure patients, who need left ventricular assistant devices.

The trial is funded by the United States National Institute of Health and the Canadian Institute of Health Research.

Currently about there is about 50,000 end-stage heart failure patients in the US and there’s a 50 per cent chance (with maximum therapy) of surviving one year. 

Mesoblast says its therapy should have a substantial positive impact on patients.

Shares in Mesoblast (ASX:MSB) are trading 0.36 per cent higher to $1.38.


Jessica Amir

Finance News Network
Jessica joined FNN in January 2017 with a passion for equities and funds management. As Head of News, she has been a broadcast journalist for over seven years, specialising in finance. She has been a journalist with Sky News Business, ABC 1, ABC's The Business and ABC24. She’s also worked as a TV reporter for regional Channel 7 and 9. She also previously worked as a financial planner and real estate agent.